2m 2m 2m 2m 2m 2m 2m
PHATHOM PHARMA (PHAT)
NASDAQ
$10.85+$0.16 (+1.46%)
Price as of Jun 23, 2026 5:10 PM EDT- $852.6MMarket Cap
- 12.88%1-Year Change
- BiotechnologyIndustry
PHATHOM PHARMA (PHAT)
$10.85+$0.16 (+1.46%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 175.1M +216.93% | 55.3M +8,001.47% | 682,000 N/A | N/A N/A | |
Cost of Revenue | 22.6M +183.44% | 8.0M +4,674.25% | 167,000 N/A | N/A N/A | |
Gross Profit | 152.5M +222.58% | 47.3M +9,080.39% | 515,000 N/A | 0 N/A | |
Sales and Marketing Expense | 279.7M -3.77% | 290.7M +146.48% | 117.9M N/A | N/A N/A | |
Research and Development Expense | -32.8M -3.82% | -34.1M -31.70% | -49.9M -30.15% | -71.4M -1.24% | |
Depreciation and Amortization Expense | 633,000 -20.38% | 795,000 +38.26% | 575,000 -7.26% | 620,000 +19.00% | |
Total Operating Expenses | 312.5M -3.77% | 324.7M +93.50% | 167.8M -2.68% | 172.4M +27.66% | |
Operating Profit | -160.0M -42.34% | -277.5M +65.84% | -167.3M -2.97% | -172.4M +27.66% | |
Interest Income | 7.0M -53.53% | 15.2M +92.46% | 7.9M +269.42% | 2.1M +5,100.00% | |
Interest Expense | -29.0M +25.00% | -23.2M -44.72% | -42.0M +53.70% | -27.3M +302.25% | |
Interest Income and Expense and Net | -22.0M +173.02% | -8.0M -76.41% | -34.1M +35.43% | -25.2M +273.10% | |
Total Nonoperating Income and Expense | -61.3M +7.74% | -56.9M +65.87% | -34.3M +35.59% | -25.3M +187.21% | |
Income before Taxes | -160.0M -42.34% | -277.5M +65.84% | -167.3M -2.97% | -172.4M +27.66% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -221.2M -33.82% | -334.3M +65.84% | -201.6M +1.96% | -197.7M +37.42% | |
Net Income from Continuing Operations Applicable to Common | -221.2M -33.82% | -334.3M +65.84% | -201.6M +1.96% | -197.7M +37.42% | |
Basic EPS and Net Income | -3.03 -42.72% | -5.29 +34.61% | -3.93 -22.18% | -5.05 +29.82% | |
Diluted EPS and Net Income | -3.03 -42.72% | -5.29 +34.61% | -3.93 -22.18% | -5.05 +29.82% | |
Basic Weighted Average Shares | 72.9M +15.42% | 63.2M +23.18% | 51.3M +31.11% | 39.1M +5.72% | |
Diluted Weighted Average Shares | 72.9M +15.42% | 63.2M +23.18% | 51.3M +31.11% | 39.1M +5.72% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 130.0M -56.28% | 297.3M -22.06% | 381.4M +145.45% | 155.4M -15.21% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 130.0M -56.28% | 297.3M -22.06% | 381.4M +145.45% | 155.4M -15.21% | |
Total Current Assets | 229.0M -36.42% | 360.1M -9.38% | 397.4M +147.60% | 160.5M -13.95% | |
Accumulated Depreciation | 3.5M +22.32% | 2.8M +38.86% | 2.0M +39.09% | 1.5M +72.65% | |
Property and Plant and Equipment and Net | 1.1M -27.91% | 1.5M -31.22% | 2.1M +77.80% | 1.2M +85.69% | |
Total Long-Term Assets | 2.9M +72.30% | 1.7M +0.06% | 1.7M +465.89% | 299,000 -12.32% | |
Total Assets | 259.1M -31.50% | 378.3M -8.58% | 413.8M +151.10% | 164.8M -13.00% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 N/A | 0 N/A | 0 N/A | N/A N/A | |
Total Current Liabilities | 132.0M +54.03% | 85.7M +121.06% | 38.8M +47.81% | 26.2M +38.67% | |
Total Long-Term Debt | 209.1M +3.81% | 201.4M +46.12% | 137.8M +44.69% | 95.3M +6.24% | |
Total Long-Term Liabilities | 4.0M -65.22% | 11.5M +18.56% | 9.7M +29.33% | 7.5M 0.00% | |
Total Liabilities | 697.3M +10.35% | 631.9M +29.86% | 486.6M +103.07% | 239.6M +104.33% | |
Retained Earnings | -1.5B +17.52% | -1.3B +36.00% | -928.7M +27.73% | -727.1M +37.35% | |
Total Stockholders Equity | -438.2M +72.79% | -253.6M +248.52% | -72.8M -2.75% | -74.8M -203.68% | |
Total Shares Outstanding | 71.4M +23.20% | 58.0M 0.00% | 58.0M +39.79% | 41.5M +35.91% | |
Cash Flow | |||||
Cash from Operating Activities | -166.8M -37.48% | -266.8M +93.90% | -137.6M -6.11% | -146.5M -1.40% | |
Capital Expenditures | 229,000 +69.63% | 135,000 -91.74% | 1.6M +56.96% | 1.0M +217.38% | |
Cash from Investing Activities | -229,000 +69.63% | -135,000 -91.74% | -1.6M +56.96% | -1.0M +217.38% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -288,000 -100.16% | 182.8M -50.28% | 367.6M +206.21% | 120.0M +168.50% | |
Financials Ratio | |||||
Gross Margin | 87.09% +1.78% | 85.57% +13.32% | 75.51% N/A | N/A N/A | |
Operating Margin | -91.36% -81.81% | -502.18% -97.95% | -24,532.55% N/A | N/A N/A | |
Return on Assets | -69.41% -17.76% | -84.41% +21.14% | -69.68% -37.58% | -111.63% +87.97% | |
Return on Equity | 63.97% -68.78% | 204.89% -25.00% | 273.21% -98.16% | 14,877.58% +13,874.35% | |
Revenue Growth | 216.93% -97.29% | 8,001.47% N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.73 -58.72% | 4.20 -59.01% | 10.25 +67.51% | 6.12 -37.94% | |
Cash Ratio | 0.98 -71.61% | 3.47 -64.74% | 9.83 +66.06% | 5.92 -38.85% | |
Debt-to-Equity Ratio | -0.48 -39.92% | -0.79 -58.07% | -1.89 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.81 +51.54% | 0.53 +59.83% | 0.33 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow